BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BioCardia, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.90−0.02 (-2.46%)
Close on Oct 19, 2026
- Market cap
- $10.85M
- P/E (TTM)
- –
- Dividend yield
- –
BioCardia, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Agreement [Member] | $13.00K | $357.00K | $43.00K | $64.00K | $106.00K | $210.00K | $974.00K | $59.00K | $79.00K | $820.00K | $69.00K | $46.00K | 100.0% | -87.7% |
| Product [Member] | $0 | $0 | $0 | $0 | $0 | $2.00K | $0 | $1.00K | $0 | $1.00K | $0 | $0 | 0.0% | – |
By region
From the segment and revenue-disaggregation notes of BioCardia's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.